Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613568 | PMC |
| http://dx.doi.org/10.1158/1535-7163.MCT-19-0470 | DOI Listing |
Publication Analysis
Top Keywords
retraction obatoclax
4
obatoclax interacts
4
interacts synergistically
4
synergistically irreversible
4
irreversible proteasome
4
proteasome inhibitor
4
inhibitor carfilzomib
4
carfilzomib gc-
4
gc- abc-dlbcl
4
abc-dlbcl cells
4
Similar Publications
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Mol Cancer Ther
May 2012
Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Interactions between the irreversible proteasome inhibitor carfilzomib and the pan-BH3 mimetic obatoclax were examined in germinal center (GC)- and activated B-cell-diffuse large B-cell lymphoma (ABC-DLBCL) cells. Cotreatment with minimally toxic concentrations of carfilzomib (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!